Arovella Therapeutics (ALA) Stock Overview

Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally. Its product pipeline includes ZolpiMist, an oral spray of zolpidem tartrate to treat insomnia, which is marketed under the brand name of Ambien or Stilnox; and invariant natural killer T (iNKT), a cell therapy platform to treat blood cancer. It has a collaborative research agreement with Imperial College London. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia.

ALA Stock Information

Symbol

ALA

Address

Corporate OncePreston, VIC 3072Australia

Founded

Trading hours

10:00 AM - 4:00 PM AEST

Website

https://www.arovella.com

Country

🇦🇺 Australia

Phone Number

61 3 9863 6472

Arovella Therapeutics (ALA) Price Chart

Arovella Therapeutics Overview: Key Details and Summary

Stock data	2023	Change
Price	$0.09809161079954809	N/A
Market Cap	$69.79M	N/A
Shares Outstanding	711.48M	29.45%
Employees	0	N/A
Shareholder Equity	3.78M	-50.37%

Valuation	2023	Change
P/E Ratio	-6.86	N/A
P/S Ratio	254.17	N/A
P/B Ratio	18.46	N/A

Growth	2023	Change
Return on Equity	-1.8221	N/A

Earnings	2023	Change
Revenue	$274.59K	N/A
Earnings	-$6.89M	N/A
EPS	-0.0143	N/A
Earnings Yield	-0.1458	N/A
Gross Margin	0.4986	N/A
Operating Margin	-23.85	N/A
Net income margin	-25.08	N/A

Financial Strength	2023	Change
Total Assets	$3.70M	N/A
Cash on Hand	$3.50M	N/A
Debt to Equity	0.3026	113.57%
Current Ratio	$3.22	-26.18%